Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06555796 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Name: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer — clinical trial record (NCT06555796)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorAmgen

Started2024-09-23

View on ClinicalTrials.gov ↗

The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).

Amendment history 2 changes detected by DataLookout

2026-09-05

Primary completion pushed: 2026-10-08 → 2027-03-13

2026-09-05

Completion pushed: 2028-12-02 → 2029-05-07

Trial Details

NCT Number	NCT06555796
Lead Sponsor	Amgen
Conditions	Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Enrollment	50 participants
Start Date	2024-09-23
Primary Completion	2027-03-13 (estimated)
Study Completion	2029-05-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-04